What they were paid
Atea Pharmaceuticals Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $62,500 | $96,200 | $90,702 | — | $249,402 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Atea Pharmaceuticals, Inc. DEF 14A filed April 27, 2026, accession 0001193125-26-182293, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Atea Pharmaceuticals pays directors a $45,000 cash retainer and $186,902 in Options and RSUs.
Committees
FY2025 · as the proxy prints themAudit · Compensation
The rest of the Atea Pharmaceuticals board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Arthur Kirsch | Independent Director | $415,333 |
| Barbara Duncan | Independent Director | $256,902 |
| Bruce Polsky | Independent Director | — |
| Franklin Berger | Independent Director | $282,902 |
| Howard Berman | Independent Director | $407,114 |
| Jean-Pierre Sommadossi | Chair of the Board | $0 |
| Jerome Adams | Independent Director | — |
| Polly Murphy | Independent Director | — |
The full Atea Pharmaceuticals compensation record
free company briefThis page is one director within Atea Pharmaceuticals's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat